Skip to contentD
Dare Bioscience, Inc.
D
DAREDare Bioscience, Inc. Q4 2023 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$1.81M$1.81Mderivedno prior Q4 2022 on file Net Income-$5.06M-$5.06MderivedN/M vs Q4 2022 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Dare Bioscience, Inc. · CIK 1401914 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$5,171,460N/M Operating Cash Flowderived-$8,178,905N/M Free Cash Flowderived-$8,786,236N/M Margins · derivedOperating margin-286.1%
Net margin-279.8%
ended Dec 31, 2023 · filed Mar 28, 2024 · 88 d after period end